IMV Inc. (IMVIQ) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
DELISTED
What happened to IMV Inc. (IMVIQ) stock?
IMV Inc. (IMVIQ) no longer trades on public markets. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
IMV Inc. (IMVIQ). IMV Inc. is a clinical-stage immuno-oncology company focused on developing DPX-based therapies for solid and hematological cancers. Their lead drug candidate, maveropepimut-S, is undergoing clinical trials for various cancers. Sector: Healthcare.
Last analyzed: Mar 16, 2026Analyst Coverage for IMVIQ: IMVIQ does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates IMVIQ against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
IMVIQ: 1/2 scored disciplines lean bearish. Dominant signal: Jim Simons bearish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
IMV Inc. (IMVIQ) Healthcare & Pipeline Overview
IMV Inc., a clinical-stage immuno-oncology company, leverages its DPX platform to develop immunotherapies targeting survivin-expressing cells in cancers. Their lead candidate, maveropepimut-S, is in Phase II trials for lymphoma, ovarian, and other cancers, positioning them within the competitive biotechnology landscape.
What Is the Investment Thesis for IMVIQ?
IMV Inc. presents a high-risk, high-reward investment opportunity within the immuno-oncology space. The investment thesis hinges on the successful clinical development and eventual commercialization of maveropepimut-S and other DPX-based therapies. Positive Phase II trial results for maveropepimut-S in various cancer indications could serve as a significant catalyst, potentially leading to partnerships or acquisition. However, the company's reliance on a single technology platform and the inherent risks associated with clinical trials pose significant challenges. Investors should closely monitor clinical trial data, regulatory milestones, and the company's ability to secure funding to support its operations. The market capitalization of $0.00B reflects the speculative nature of the investment.
Based on FMP financials and quantitative analysis
IMVIQ Key Highlights
Maveropepimut-S is in Phase II clinical trials for diffuse large B cell lymphoma, ovarian cancer, bladder cancer, liver cancer, and MSI-H solid tumors, indicating progress in multiple cancer indications.
- DPX platform is a key differentiator, offering a novel approach to immune-educating technology for cancer treatment.
- The company has a pipeline of therapies, including DPX-SurMAGE and DPX-COVID-19, indicating potential for future growth beyond maveropepimut-S.
- IMV Inc. changed its name from Immunovaccine Inc. in May 2018, reflecting a strategic shift in its corporate identity and focus.
- The company has 63 employees, indicating a relatively small size and potential for agility in its operations.
Who Are IMVIQ's Competitors?
IMVIQ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| NVO Novo Nordisk A/S | $44.01 | -1.23% | $195B | 925-pillar |
| VRTX Vertex Pharmaceuticals Incorporated | $514.90 | +0.07% | $131B | 965-pillar |
| REGN Regeneron Pharmaceuticals, Inc. | $793.26 | -1.78% | $81.7B | 945-pillar |
| ARGX argenx SE | $984.04 | -1.82% | $61.2B | 975-pillar |
| ALNY Alnylam Pharmaceuticals, Inc. | $247.51 | -4.07% | $33.1B | 895-pillar |
| RPRX Royalty Pharma plc | $58.75 | -3.04% | $26.0B | 725-pillar |
| INCY Incyte Corporation | $121.47 | -1.47% | $24.6B | 985-pillar |
| UTHR United Therapeutics Corporation | $503.86 | -0.58% | $21.4B | 975-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are IMVIQ's Key Strengths?
Proprietary DPX platform technology.
- Maveropepimut-S in Phase II clinical trials.
- Potential for expansion into new cancer indications.
- Experienced management team.
What Are IMVIQ's Weaknesses?
Reliance on a single technology platform.
- Limited financial resources.
- High risk of clinical trial failure.
- Competition from larger pharmaceutical companies.
What Could Drive IMVIQ Stock Higher?
IMVIQ catalyst: Release of Phase II clinical trial data for maveropepimut-S in diffuse large B cell lymphoma.
- Initiation of Phase II clinical trials for maveropepimut-S in additional cancer indications.
- Enrollment of patients in ongoing clinical trials.
- Potential partnerships or collaborations with pharmaceutical companies.
- Advancement of DPX-SurMAGE into later-stage clinical trials.
What Are the Key Risks for IMVIQ?
Financial-distress signal — its Altman Z-Score of -11.97 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for maveropepimut-S or DPX-SurMAGE.
- Regulatory hurdles and delays in obtaining FDA approval.
- Competition from other immuno-oncology companies.
- Limited financial resources and the need to raise additional capital.
- Dependence on a single technology platform.
What Are the Growth Opportunities for IMVIQ?
- Expansion of Maveropepimut-S into New Indications: IMV Inc. has the opportunity to expand the use of maveropepimut-S into additional cancer indications beyond its current Phase II trials. This could involve targeting other solid tumors or hematological malignancies that express survivin. The market for cancer therapies is vast, with each new indication representing a potential multi-billion dollar opportunity. Success in new indications would significantly increase the commercial potential of maveropepimut-S.
- Advancement of DPX-SurMAGE: The development of DPX-SurMAGE, currently in Phase I clinical trials for bladder cancer, represents another growth opportunity for IMV Inc. If successful, DPX-SurMAGE could provide a new treatment option for bladder cancer patients, addressing a significant unmet need. The bladder cancer market is expected to grow in the coming years, driven by an aging population and increasing incidence rates. Positive clinical trial results for DPX-SurMAGE would be a major catalyst for IMV Inc.
- Partnerships and Collaborations: IMV Inc. can pursue partnerships and collaborations with larger pharmaceutical companies to accelerate the development and commercialization of its DPX-based therapies. These partnerships could provide access to funding, expertise, and resources that would otherwise be unavailable to IMV Inc. The pharmaceutical industry is actively seeking innovative cancer therapies, making partnerships a viable growth strategy. Successful partnerships could lead to significant financial gains for IMV Inc.
- Expansion into Infectious Diseases: IMV Inc. is exploring the potential of its DPX platform for infectious diseases, with DPX-COVID-19 and DPX-RSV in development. While these programs are in early stages, they represent a potential growth opportunity for the company. The market for vaccines and therapies for infectious diseases is substantial, particularly in the wake of the COVID-19 pandemic. Success in this area could diversify IMV Inc.'s product pipeline and revenue streams.
- Out-Licensing or Acquisition: IMV Inc. could pursue an out-licensing agreement or be acquired by a larger pharmaceutical company. Positive clinical trial results for maveropepimut-S or DPX-SurMAGE would make IMV Inc. an attractive acquisition target. An acquisition would provide IMV Inc.'s shareholders with a significant return on their investment. The pharmaceutical industry is constantly consolidating, making acquisitions a common occurrence.
What Are IMVIQ's Competitive Advantages?
- Proprietary DPX platform technology.
- Clinical trial data supporting the efficacy of maveropepimut-S.
- Intellectual property protection for their therapies.
- Experienced management team with expertise in immuno-oncology.
What Does IMVIQ Do?
Founded in 2000 and headquartered in Dartmouth, Canada, IMV Inc. (formerly Immunovaccine Inc.) is a clinical-stage immuno-oncology company dedicated to developing novel cancer therapies. The company's core technology, the DPX platform, is designed to educate the immune system to recognize and attack cancer cells. Their lead drug candidate, maveropepimut-S, a DPX-based immunotherapy, targets survivin, a protein commonly expressed in cancer cells. Maveropepimut-S is currently in Phase II clinical trials for diffuse large B cell lymphoma, ovarian cancer, bladder cancer, liver cancer, and MSI-H solid tumors. Additionally, it is in Phase I clinical trials for breast cancer. IMV Inc. is also developing DPX-SurMAGE, which is in Phase I clinical trial for bladder cancer, and exploring the potential of its DPX platform for infectious diseases with DPX-COVID-19 and DPX-RSV. The company focuses on addressing unmet needs in cancer treatment through its innovative immunotherapy approaches.
What Products and Services Does IMVIQ Offer?
- Develop immunotherapies for cancer treatment.
- Utilize the DPX platform to educate the immune system to target cancer cells.
- Conduct clinical trials to evaluate the safety and efficacy of their therapies.
- Focus on solid and hematological cancers.
- Target survivin-expressing cells in cancer.
- Explore the potential of the DPX platform for infectious diseases.
How Does IMVIQ Make Money?
- Develop and commercialize DPX-based immunotherapies.
- Generate revenue through partnerships and collaborations with pharmaceutical companies.
- Potentially generate revenue through out-licensing agreements or an acquisition.
- Secure funding through venture capital and public offerings.
What Industry Does IMVIQ Operate In?
IMV Inc. operates within the competitive and rapidly evolving immuno-oncology market. This market is characterized by intense research and development efforts, with numerous companies vying to develop innovative cancer therapies. IMV Inc.'s DPX platform positions it as a player in the development of personalized cancer immunotherapies, competing with larger pharmaceutical companies and specialized biotech firms.
Who Are IMVIQ's Key Customers?
- Cancer patients.
- Pharmaceutical companies.
- Healthcare providers.
- Research institutions.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price 5 days old
- ● No filing on record
- ● No analyst coverage
MoonshotScore History
Recorded daily since 2026-08-23 · 4 snapshots
| 2026-08-23 | 44 |
| 2026-08-24 | 44 |
| 2026-08-25 | 44 |
| 2026-08-26 | 44 |
What changed?
The score has stayed at 44.
Over the same 3 days the stock moved +0.0%.
Company Profile
IMV Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Dartmouth, CA. The company is led by CEO Andrew Hall. IMVIQ has traded publicly since 2009.
Financial Health
IMV Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -11.97 places it in the distress zone, a signal of elevated financial risk.
Earnings Track Record
IMV Inc. has beaten Wall Street's EPS estimate in 3 of its last 5 reported quarters — more hits than misses. Reported results have landed about 3.9% above estimates on average.
Forward Outlook
Wall Street analysts project IMV Inc. revenue of about $21.9M for fiscal 2026, with EPS near $-2.69.
IMVIQ Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Proprietary DPX platform technology.
- Maveropepimut-S in Phase II clinical trials.
- Potential for expansion into new cancer indications.
- Experienced management team.
Bear Case
- Reliance on a single technology platform.
- Limited financial resources.
- High risk of clinical trial failure.
- Competition from larger pharmaceutical companies.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
IMVIQ Latest News
No recent news available for IMVIQ.
Leadership: Andrew Hall
CEO
Andrew Hall is the CEO of IMV Inc. His background includes extensive experience in the biotechnology industry, with a focus on immuno-oncology. He has held leadership positions at various pharmaceutical and biotech companies, where he was responsible for driving the development and commercialization of novel therapies. Hall has a strong track record of building and managing successful teams, and he is committed to advancing IMV Inc.'s mission of developing innovative cancer treatments.
Track Record: Under Andrew Hall's leadership, IMV Inc. has made significant progress in advancing its pipeline of DPX-based therapies. He has overseen the initiation and execution of several clinical trials, including the Phase II trials for maveropepimut-S. Hall has also been instrumental in securing funding for the company and building strategic partnerships. His leadership has been critical to IMV Inc.'s growth and development.
IMVIQ OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that IMV Inc. may not meet the minimum financial or reporting requirements for higher tiers like OTCQB or OTCQX. Companies in this tier often have limited operating history, are in financial distress, or are subject to regulatory scrutiny. Investing in companies on the OTC Other tier carries significant risks due to the lack of transparency and regulatory oversight compared to exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Potential for price manipulation due to low trading volume.
- Higher risk of fraud or mismanagement compared to listed companies.
- Limited regulatory oversight and investor protection.
- Potential for delisting or suspension of trading.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent portfolio.
- Review the company's legal and regulatory compliance.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Presence of a management team with relevant experience.
- Ongoing clinical trials for their drug candidates.
- Intellectual property protection for their technology.
- Scientific publications or presentations related to their research.
- Company headquarters located in Canada.
IMVIQ Healthcare Stock FAQ
What happened to IMV Inc. (IMVIQ) stock?
IMV Inc. (IMVIQ) no longer trades on public markets. The figures below are historical and are not a current quote.
Can I still buy IMVIQ shares?
No. IMVIQ stopped trading on public markets, so the shares are not available through a broker. Anything you see quoted for IMVIQ elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before IMVIQ stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to IMV Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does IMV Inc. do?
IMV Inc. is a clinical-stage biotechnology company focused on developing immunotherapies for the treatment of cancer. The company's proprietary DPX platform is designed to stimulate the immune system to recognize and attack cancer cells.
What do analysts say about IMVIQ stock?
Analyst coverage of IMVIQ is limited due to its OTC listing and small market capitalization. Existing analyses focus on the potential of the DPX platform and the clinical progress of maveropepimut-S.
What are the main risks for IMVIQ?
The main risks for IMV Inc. include the inherent uncertainties associated with clinical-stage drug development, including the potential for clinical trial failures and regulatory hurdles.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited analyst coverage and financial data available due to OTC listing.
- Clinical trial outcomes are inherently uncertain and could significantly impact the company's value.